IMPORTANT SHAREHOLDER ALERT: Wolf Haldenstein Adler Freeman

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
IMPORTANT SHAREHOLDER ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Class Action Lawsuit Has Been Commenced in the United States District Court for the Southern District of Texas Against Nobilis Health Corp. -- HLTH

NEW YORK, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the Southern District of Texas on behalf of all persons or entities that purchased the securities of Nobilis Health Corp. (“Nobilis” or the “Company”) (NYSE: HLTH ) between April 2, 2015 through January 6, 2016 (the “Class Period”), inclusive.

Shareholders who incurred losses on shares on purchased within the Class Period are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774.

If you purchased the shares of Nobilis Health Corp. during the period April 2, 2015 through January 6, 2016, inclusive, you may, no later than March 21, 2016 , request that the Court appoint you lead plaintiff of the proposed class.

On October 9, 2015, Seeking Alpha published an article describing the AccuraScope procedure’s “questionable insurability, unsubstantiated success rates, [and] lack of recognition from” universities, medical bodies, and insurance companies. The article additionally noted significant accounting red flags at Nobilis and reported that Nobilis had overstated its 2014 revenues by as much as $36 million. On this news, the price of Nobilis common stock fell $1.42 per share, or 27% from its closing price of $5.24 on October 8, 2015 to close at $3.82 per share on October 9, 2015.

In a January 5, 2016 Form 8-K filed with the Securities and Exchange Commission (“SEC”), Nobilis disclosed that its financial statements for the fiscal year ended December 31, 2014, the quarters ended March 31, 2015 and June 30, 2015 and the financial statements in its updated S-1 registration statement filed with the SEC on October 23, 2015 could no longer be relied upon.

Subsequently, on January 7, 2016, Nobilis announced that Christopher J.Lloyd had resigned as the Company’s Chief Executive Officer. On this news, Nobilis stock fell $0.63, or more than 20%, to close at $2.47 on January 7, 2016.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at classmember@whafh.com , or visit our website at www.whafh.com.   All e-mail correspondence should make reference to the “Nobilis Investigation.”

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.

 

Contact: Wolf Haldenstein Adler Freeman & Herz LLP Patrick Donovan, Esq. Gregory Stone, Director of Case and Financial Analysis Email: gstone@whafh.com, donovan@whafh.com or classmember@whafh.com Tel: (800) 575-0735 or (212) 545-4774

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

2026 Cannabis Reform: A Turning Point for Stock Valuations

Updated Category News Views 214

2026 Cannabis Reform: A Turning Point for Stock Valuations As we approach the end of 2025, the cannabis sector showcases a perplexing scenario for investors. Political events are creating uncertainty yet also opportunities within this evolving market. Recently, a significant Executive Order was issued, calling for a swift review of cannabis scheduling. A change like this...

Continue Reading
21Shares Unveils Innovative 2x Long Dogecoin ETF TXXD

Updated Category News Views 195

Introduction to the 21Shares 2x Long Dogecoin ETF 21Shares has recently made headlines by launching the 21Shares 2x Long Dogecoin ETF (Ticker: TXXD). This innovative exchange-traded fund enables investors to gain leveraged exposure to Dogecoin, a cryptocurrency that has gained immense popularity and support from its enthusiastic community. Designed to trade on NASDAQ,...

Continue Reading
Bicara Therapeutics Completes Impressive $362 Million IPO Success

Updated Category News Views 149

Bicara Therapeutics' Initial Public Offering: An Overview Bicara Therapeutics Inc. has achieved a remarkable milestone by completing its initial public offering (IPO) and raising about $362 million. This offering included 20,125,000 shares of common stock, each priced at $18.00. Significantly, the IPO's success also reflects the full exercise of the underwriters' option,...

Continue Reading
Marshall Group Continues Strong Growth in Third Quarter 2024

Updated Category News Views 439

Marshall Group Reports Impressive Growth in Q3 2024 In the latest financial update, Marshall Group has demonstrated remarkable performance, continuing its trajectory of profitable growth. With a 15 percent increase in net sales, reaching SEK 1,118.4 million, the company highlights its commitment to excellence and innovation. This growth is accompanied by an adjusted...

Continue Reading
Innovative Psilocybin Training Program Launches in Colorado

Updated Category News Views 169

InnerTrek Launches New Psychedelic Facilitator Training Program InnerTrek has just opened applications for an exciting training program designed for future psychedelic practitioners. This initiative marks a significant development in the realm of psychedelic healthcare. Available virtually, it welcomes students from all corners of the globe to join in and learn....

Continue Reading